Vaxzevria COVID-19 Vaccine: Further advice on blood clots and low blood platelets
EMA has provided additional advice on blood clots or low blood platelets occurring after vaccination with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).
EMA’s human medicines committee (CHMP) is recommending that healthcare professionals:
While blood clots with low blood platelets following vaccination are very rare, EMA continues to advise people to be aware of symptoms (see below), so they can receive prompt specialised medical treatment if needed.
The updated EMA recommendations for healthcare professionals are available in the vaccine’s product information. As for all vaccines, EMA and national authorities continuously monitor the safety of Vaxzevria and will update recommendations when necessary, to protect public health.
Information for the public
Information for healthcare professionals
Healthcare professionals will receive a direct healthcare professional communication (DHPC) with the information above. The DHPC will also be available on a dedicated page on the EMA website.
More about the medicine
Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus. Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making the S protein from SARS-CoV-2. The vaccine does not contain the virus itself and cannot cause COVID-19.
The most common side effects are usually mild or moderate and improve within a few days after vaccination.
More about the procedure
EMA’s safety committee (PRAC) and human medicines committee (CHMP) conducted this review of Vaxzevria in the context of a procedure known as a ‘type II variation’. The European Commission will issue a legally binding decision valid throughout the EU.
More information on EMA reviews concerning blood clots and low blood platelets with Vaxzevria, including the latest safety updates, is available on EMA’s website.
Relevant Press Releases